Medpace Holdings, Inc. Financing Cash Flow
Medpace Holdings, Inc. (MEDP) reported Financing Cash Flow of -$275.67 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-07-23
- Medpace Holdings, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was -$288.34M.
- Medpace Holdings, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $12.67M.
- Medpace Holdings, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $22.73M.
- Medpace Holdings, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $3.41M, a 45.60% decline year-over-year.
- Medpace Holdings, Inc. net cash provided by (used in) financing activities for fiscal 2025 was -$860.39M.
- Medpace Holdings, Inc. net cash provided by (used in) financing activities for fiscal 2024 was -$154.01M.
- Medpace Holdings, Inc. net cash provided by (used in) financing activities for fiscal 2023 was -$182.64M.
- Medpace Holdings, Inc. net cash provided by (used in) financing activities for fiscal 2022 was -$775.77M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$288.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-23 | -$275.67M 10-Q · filed 2026-07-23 | -$252.94M derived: sum of 3 quarters · filed 2026-07-23 | -$249.53M derived: sum of 4 quarters · filed 2026-07-23 |
| 2026-03-31 | $12.67M 10-Q · filed 2026-04-23 | $35.40M derived: sum of 2 quarters · filed 2026-04-23 | $38.81M derived: sum of 3 quarters · filed 2026-04-23 | -$501.75M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-12-31 | $22.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $26.14M derived: sum of 2 quarters · filed 2026-02-10 | -$514.42M derived: sum of 3 quarters · filed 2026-07-23 | -$860.39M 10-K · filed 2026-02-10 |
| 2025-09-30 | $3.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-23 | -$537.15M derived: sum of 2 quarters · filed 2026-07-23 | -$883.12M 10-Q · filed 2025-10-23 | -$1.05B derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-06-30 | -$540.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-23 | -$886.53M 10-Q · filed 2026-07-23 | -$1.06B derived: sum of 3 quarters · filed 2026-07-23 | -$1.05B derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-03-31 | -$345.97M 10-Q · filed 2026-04-23 | -$514.58M derived: sum of 2 quarters · filed 2026-04-23 | -$508.30M derived: sum of 3 quarters · filed 2026-04-23 | -$507.63M derived: sum of 4 quarters · filed 2026-04-23 |
| 2024-12-31 | -$168.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | -$162.34M derived: sum of 2 quarters · filed 2026-02-10 | -$161.67M derived: sum of 3 quarters · filed 2026-02-10 | -$154.01M 10-K · filed 2026-02-10 |
| 2024-09-30 | $6.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-23 | $6.94M derived: sum of 2 quarters · filed 2025-10-23 | $14.60M 10-Q · filed 2025-10-23 | $16.12M derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-06-30 | $666.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-22 | $8.33M 10-Q · filed 2025-07-22 | $9.85M derived: sum of 3 quarters · filed 2026-02-10 | -$39.42M derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-03-31 | $7.66M 10-Q · filed 2025-04-22 | $9.18M derived: sum of 2 quarters · filed 2026-02-10 | -$40.09M derived: sum of 3 quarters · filed 2026-02-10 | -$122.30M derived: sum of 4 quarters · filed 2026-02-10 |
| 2023-12-31 | $1.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | -$47.75M derived: sum of 2 quarters · filed 2026-02-10 | -$129.96M derived: sum of 3 quarters · filed 2026-02-10 | -$182.64M 10-K · filed 2026-02-10 |
| 2023-09-30 | -$49.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-22 | -$131.48M derived: sum of 2 quarters · filed 2024-10-22 | -$184.16M 10-Q · filed 2024-10-22 | -$315.29M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-06-30 | -$82.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-23 | -$134.89M 10-Q · filed 2024-07-23 | -$266.01M derived: sum of 3 quarters · filed 2025-02-11 | -$375.12M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-03-31 | -$52.68M 10-Q · filed 2024-04-23 | -$183.80M derived: sum of 2 quarters · filed 2025-02-11 | -$292.91M derived: sum of 3 quarters · filed 2025-02-11 | -$416.38M derived: sum of 4 quarters · filed 2025-02-11 |
| 2022-12-31 | -$131.12M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | -$240.23M derived: sum of 2 quarters · filed 2025-02-11 | -$363.69M derived: sum of 3 quarters · filed 2025-02-11 | -$775.77M 10-K · filed 2025-02-11 |
| 2022-09-30 | -$109.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-24 | -$232.57M derived: sum of 2 quarters · filed 2023-10-24 | -$644.65M 10-Q · filed 2023-10-24 | -$642.22M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-06-30 | -$123.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-25 | -$535.55M 10-Q · filed 2023-07-25 | -$533.12M derived: sum of 3 quarters · filed 2024-02-13 | -$538.32M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-03-31 | -$412.08M 10-Q · filed 2023-04-25 | -$409.65M derived: sum of 2 quarters · filed 2024-02-13 | -$414.86M derived: sum of 3 quarters · filed 2024-02-13 | -$465.64M derived: sum of 4 quarters · filed 2024-02-13 |
| 2021-12-31 | $2.43M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-13 | -$2.78M derived: sum of 2 quarters · filed 2024-02-13 | -$53.55M derived: sum of 3 quarters · filed 2024-02-13 | -$44.45M 10-K · filed 2024-02-13 |
| 2021-09-30 | -$5.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-25 | -$55.99M derived: sum of 2 quarters · filed 2022-10-25 | -$46.88M 10-Q · filed 2022-10-25 | -$87.09M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-06-30 | -$50.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-26 | -$41.68M 10-Q · filed 2022-07-26 | -$81.89M derived: sum of 3 quarters · filed 2023-02-14 | -$75.11M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-03-31 | $9.10M 10-Q · filed 2022-04-26 | -$31.11M derived: sum of 2 quarters · filed 2023-02-14 | -$24.33M derived: sum of 3 quarters · filed 2023-02-14 | -$32.73M derived: sum of 4 quarters · filed 2023-02-14 |
| 2020-12-31 | -$40.21M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | -$33.43M derived: sum of 2 quarters · filed 2023-02-14 | -$41.84M derived: sum of 3 quarters · filed 2023-02-14 | -$82.28M 10-K · filed 2023-02-14 |
| 2020-09-30 | $6.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-26 | -$1.63M derived: sum of 2 quarters · filed 2021-10-26 | -$42.07M 10-Q · filed 2021-10-26 | -$41.24M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | -$8.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-27 | -$48.85M 10-Q · filed 2021-07-27 | -$48.02M derived: sum of 3 quarters · filed 2022-02-15 | -$46.22M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | -$40.45M 10-Q · filed 2021-04-27 | -$39.61M derived: sum of 2 quarters · filed 2022-02-15 | -$37.82M derived: sum of 3 quarters · filed 2022-02-15 | -$91.33M derived: sum of 4 quarters · filed 2022-02-15 |
| 2019-12-31 | $834.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $2.63M derived: sum of 2 quarters · filed 2022-02-15 | -$50.89M derived: sum of 3 quarters · filed 2022-02-15 | -$73.92M 10-K · filed 2022-02-15 |
| 2019-09-30 | $1.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-27 | -$51.72M derived: sum of 2 quarters · filed 2020-10-27 | -$74.75M 10-Q · filed 2020-10-27 | -$108.60M derived: sum of 4 quarters · filed 2021-02-16 |
| 2019-06-30 | -$53.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-28 | -$76.55M 10-Q · filed 2020-07-28 | -$110.39M derived: sum of 3 quarters · filed 2021-02-16 | -$160.14M derived: sum of 4 quarters · filed 2021-02-16 |
| 2019-03-31 | -$23.03M 10-Q · filed 2020-04-29 | -$56.88M derived: sum of 2 quarters · filed 2021-02-16 | -$106.62M derived: sum of 3 quarters · filed 2021-02-16 | -$140.60M derived: sum of 4 quarters · filed 2021-02-16 |
| 2018-12-31 | -$33.85M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-16 | -$83.59M derived: sum of 2 quarters · filed 2021-02-16 | -$117.57M derived: sum of 3 quarters · filed 2021-02-16 | -$141.58M 10-K · filed 2021-02-16 |
| 2018-09-30 | -$49.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-29 | -$83.72M derived: sum of 2 quarters · filed 2019-10-29 | -$107.73M 10-Q · filed 2019-10-29 | -$130.97M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-06-30 | -$33.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-30 | -$57.98M 10-Q · filed 2019-07-30 | -$81.22M derived: sum of 3 quarters · filed 2020-02-25 | -$123.36M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-03-31 | -$24.01M 10-Q · filed 2019-04-30 | -$47.24M derived: sum of 2 quarters · filed 2020-02-25 | -$89.39M derived: sum of 3 quarters · filed 2020-02-25 | |
| 2017-12-31 | -$23.23M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | -$65.38M derived: sum of 2 quarters · filed 2020-02-25 | -$97.83M 10-K · filed 2020-02-25 | |
| 2017-09-30 | -$42.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-30 | -$74.59M 10-Q · filed 2018-10-30 | ||
| 2017-06-30 | -$32.45M 10-Q · filed 2018-07-31 | |||
| 2016-12-31 | -$58.01M 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |